CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer and Crysvita burosumab (KRN23, UX023) to treat X-linked hypophosphataemia (XLH). The committee did

Read the full 480 word article

User Sign In